Cardiovascular And Soft Tissue Repair Patches Market (2026 - 2033)

Cardiovascular And Soft Tissue Repair Patches Market Summary

The global cardiovascular and soft tissue repair patches market size was valued at USD 5.2 billion in 2025 and is projected to grow from USD 5.6 billion in 2026 to USD 9.7 billion by 2033, at a CAGR of 8.4% from 2026 to 2033. North America dominated the global market, accounting for a revenue share of 35.0% in 2025. A substantial congenital heart disease burden continues to support demand for surgical repair materials. The WHO reported in June 2026 that congenital heart disease affects approximately 1.35 million newborns globally each year, while about 25% of affected individuals require surgical or catheter-based intervention during infancy.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

The ongoing need for surgical reconstruction and tissue reinforcement drives demand for cardiovascular and soft-tissue repair patches. Cardiovascular applications include repair of congenital and acquired defects, while soft tissue applications include hernia repair and reconstruction. Material selection remains important, with collagen-based biological materials, synthetic polymers, and newer biomaterial approaches offering different combinations of strength, flexibility, biocompatibility, and tissue integration.

Product development is increasingly shifting toward patches that integrate more effectively with native tissue and provide improved durability, controlled degradation, and regenerative properties. Advances in biomaterials, surface modification, and tissue-engineering approaches are broadening the range of repair options while improving anatomical adaptability and long-term performance. This evolution is supporting differentiation across cardiovascular and soft-tissue repair applications.

Market Dynamics

The growth of the cardiovascular and soft tissue repair patches market is driven by the ongoing need for cardiac, vascular, and soft tissue reconstruction procedures, as well as advances in biomaterials and surgical techniques. Demand is shifting toward patches that provide mechanical reinforcement while supporting tissue integration, healing, and, in selected applications, controlled resorption. Manufacturers are expanding biologic, bioabsorbable, and tissue-engineered portfolios to address these requirements. The market is also benefiting from high procedure volumes in soft tissue repair, particularly hernia repair, while an aging population and persistent cardiovascular disease burden continue to support the underlying surgical base.

Analyst Perspective

The cardiovascular and soft tissue repair patches market is evolving as surgeons seek biomaterials that provide reliable tissue reinforcement, promote healing, and reduce complications. Demand spans cardiovascular reconstruction, vascular repair, hernia repair, and other soft tissue procedures, with product selection influenced by durability, biocompatibility, handling, and infection resistance. Manufacturers are developing advanced synthetic and biologic patches with improved flexibility, tissue integration, and application-specific performance. Growing cardiovascular and reconstructive procedures, along with advances in minimally invasive surgery, are supporting market development. Clinical evidence, regulatory requirements, cost, and surgeon familiarity remain important adoption factors. Future competition will increasingly focus on biomaterial innovation, tissue compatibility, procedure-specific designs, consistent clinical outcomes, and ease of surgical handling.

Application Insights

The soft tissue repair segment dominated the cardiovascular and soft tissue repair patches industry, accounting for an estimated revenue share of 47.5% in 2025, supported by the large and recurring volume of hernia and other soft tissue reconstruction procedures. The FDA estimates that up to 1 million hernia repairs are performed annually in the U.S., with surgical mesh used in most repairs to reinforce weakened tissue. Demand spans inguinal, ventral, incisional, and umbilical hernia procedures, while product development increasingly focuses on balancing mechanical reinforcement with tissue integration, resorption, and postoperative complication profiles.

The cardiac repair segment is expected to grow at a significant CAGR of 18.5% over the forecast period, as surgical treatment of congenital and acquired structural heart conditions sustains demand for materials used in defect closure and cardiovascular reconstruction. Congenital heart disease remains an important application area, particularly in pediatric surgery, although treatment approaches vary by defect and may include direct suture closure, surgical patches, or transcatheter devices. Material innovation is also broadening the range of cardiac repair patches. For example, Teijin’s SYNFOLIUM, launched in Japan in June 2024 following approval in July 2023, combines bioabsorbable and non-bioabsorbable yarns with cross-linked gelatin and was developed to support tissue regeneration while accommodating physiological growth.

Raw Material Insights

The ePTFE segment accounted for an estimated 56.7% of market revenue in 2025, supported by the material’s combination of tensile strength, durability, chemical stability, and established use in medical-device applications. Its processing flexibility allows manufacturers to produce ePTFE products with different thicknesses, pore structures, and configurations for cardiovascular repair and tissue reinforcement. The material is also used in other medical-device applications, supporting an established manufacturing and supply base. However, biomaterials and tissue-engineered materials are expected to grow faster as manufacturers develop patches designed to improve tissue integration, enable controlled degradation, and promote regenerative healing.

Biomaterials and tissue-engineered materials are expected to grow at a CAGR of 10.0% over the forecast period. Bovine pericardium remains a widely used biological material for cardiovascular and soft tissue repair patches. Its collagen-rich structure provides flexibility, strength, and good conformability to different anatomical sites. After processing and decellularization, the tissue can be shaped into patches of different sizes for various surgical applications. Ongoing biomaterial development focuses on improving durability, biocompatibility, tissue integration, and resistance to calcification and other complications.

Regional Insights

North America accounted for an estimated 35.0% of the cardiovascular and soft tissue repair patches market revenue in 2025, supported by a substantial procedural base, advanced healthcare infrastructure, and availability of specialized surgical technologies. The U.S. alone performs as many as 1 million hernia repairs annually, with surgical mesh used in most repairs, providing a sizeable application base for soft tissue repair products. The region also has an established cardiovascular care ecosystem and continued demand for congenital and acquired heart repair procedures—availability of advanced biomaterials, established medical-device manufacturing capabilities, and ongoing product development further support regional adoption.

To learn more about this report, Download Free Sample Report

The U.S. is a major demand center in the North America cardiovascular and soft tissue repair patches industry, due to its high volume of hernia procedures and sustained need for cardiovascular interventions. The rising procedural volumes, along with access to specialized surgical products and a mature regulatory and healthcare infrastructure, create broad commercial demand for cardiovascular and soft-tissue repair patches.

Asia Pacific Cardiovascular And Soft Tissue Repair Patches Market Trends

The Asia Pacific cardiovascular and soft tissue repair patches industry is anticipated to grow at the fastest CAGR of 11.0% over the forecast period, supported by expanding healthcare infrastructure, a large and aging population, a rising burden of cardiovascular disease, and improving access to specialized surgical care. The WHO South-East Asia Region recorded more than 4.25 million cardiovascular disease deaths in 2021, with nearly half occurring prematurely among people aged 30–69 years, highlighting the substantial regional need for cardiovascular diagnosis and treatment.

Growing adoption of advanced surgical technologies, improvements in congenital heart disease detection, and expanding treatment capacity in countries such as China, India, and Japan are also supporting demand for cardiovascular repair products. As healthcare systems strengthen their ability to provide timely diagnosis and intervention, opportunities for surgical patches used in cardiac reconstruction and soft tissue repair are expected to broaden.

Key Cardiovascular And Soft Tissue Repair Patches Company Insights

Companies operating in the cardiovascular and soft tissue repair patches market are focusing on material innovation, portfolio expansion, and commercial partnerships to address different surgical requirements and broaden geographic reach. Product development is increasingly centered on improving tissue compatibility, mechanical performance, handling characteristics, and integration with existing surgical techniques. These activities reflect broader efforts by manufacturers to strengthen complementary surgical portfolios and expand access to specialized cardiovascular repair technologies.

Key Cardiovascular And Soft Tissue Repair Patches Companies

The following key companies have been profiled in this study of the cardiovascular and soft tissue repair patches market.

• Abbott Laboratories

• Artivion, Inc.

• B. Braun

• Baxter International Inc.

• CorMatrix Cardiovascular, Inc.

• Edwards Lifesciences Corporation

• Glycar SA

• GUNZE LIMITED

• Integra LifeSciences

• Labcor

• LeMaitre Vascular, Inc.

• Maverick Biosciences Pty Ltd

• Terumo Medical Corporation

• W. L. Gore & Associates, Inc.

Recent Developments

• In May 2026, Artivion received U.S. FDA PMA approval for the NEXUS Aortic Arch System, expanding its portfolio of technologies for the treatment of complex aortic arch disease, including chronic aortic dissections.

Global Cardiovascular And Soft Tissue Repair Patches Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the cardiovascular and soft tissue repair patches market report based on application, raw materials, and region:

• Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Cardiac repair
    • Atrial Septal Defect
    • Common Atrium
    • Defects of the Endocardial Cushion
    • Ventricular Septal Defect
    • Tetralogy of Fallot
    • Right Ventricular Outflow Tract Reconstruction
    • Suture Bleeding
  • Vascular Repair & Reconstruction
    • Carotid Endarterectomy
    • Anomalous Connection of the Pulmonary Veins
    • Transposition of the Great Vessels
    • Reconstruction of Portal and Superior Mesenteric Veins
    • Others
  • Pericardial Repair
  • Dural Repair
  • Soft Tissue Repair
    • Defects of the Abdominal Wall
    • Defects of the Thoracic Wall
    • Gastric Binding
    • Hernias
• Raw Material Outlook (Revenue, USD Million, 2021 - 2033)
  • ePTFE
  • Biomaterial & Tissue Engineered Material
  • Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • Spain
    • France
    • Italy
    • Russia
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa